Human point mutations in β-and γ-tropomyosin induce contractile deregulation, skeletal muscle weakness, and congenital myopathies. The aim of the present study was to elucidate the hitherto unknown underlying molecular mechanisms. Hence, we recorded and analyzed the X-ray diffraction patterns of human membranepermeabilized muscle cells expressing a particular β-tropomyosin mutation (R133W) associated with a loss in cell force production, in vivo muscle weakness, and distal arthrogryposis. Upon addition of calcium, we notably observed less intensified changes, compared with controls, (i) in the second (1/19 nm ) actin layer lines of cells set at a sarcomere length, allowing an optimal thin-thick filament overlap; and (ii) in the second actin layer line of overstretched cells. Collectively, these results directly prove that during activation, switching of a positive to a neutral charge at position 133 in the protein partially hinders both calcium-and myosin-induced tropomyosin movement over the thin filament, blocking actin conformational changes and consequently decreasing the number of cross-bridges and subsequent force production.actin | cross-bridge | single-muscle fiber | X-ray diffraction T ropomyosin is expressed in multiple isoforms in most mammalian cell types (1, 2). The isoform diversity is related to alternative splicing, alternative promoters, and differential RNA processing, resulting in specific striated muscle, smooth muscle, and nonmuscle isoforms (2). In skeletal muscle there are three major isoforms, α, β, and γ, which are encoded by the TPM1, TPM2, and TPM3 genes, respectively (2). A number of missense defects in these TPM2 and TPM3 genes cause single amino acid changes in β-and γ-tropomyosin, skeletal muscle weakness, and myopathies (3). The molecular mechanisms by which such subtle defects result in muscle contractile dysfunction remain unclear and need to be elucidated with the aim of targeting potential therapies.A unique β-tropomyosin mutation (R133W) resulting from a defect in the TPM2 gene was recently identified in patients with distal arthrogryposis and an autosomal dominant congenital myopathy (4). These patients suffered from generalized weakness in both proximal and distal muscles. Biopsy specimens did not reveal any signs of atrophy or other histopathological abnormalities (4). Nevertheless, in normal-sized fibers, cell-physiological experiments disclosed a large decrease in maximal isometric force production ( Fig. 1) as well as changes in kinetics: that is, a slower rate of force development and a faster maximum unloaded shortening velocity (5), implying a slower rate of motor protein myosin attachment and a faster rate of detachment from actin monomers. This finding suggests a reduced number of cross-bridges in the strong binding state, resulting in overall weakness in the patients (5). How does the R133W mutation induce such dysfunction? To date, at the molecular level no experimentally-based explanation exists.In skeletal muscle, tropomyosin is an integral component of the sar...